GelbDJOlverEGilmanS: Diagnostic criteria for Parkinson disease, Arch Neurol56: 33–39, 1999.
2.
HughesAJDanielSE: The accuracy of the clinical diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125: 861–870, 2002.
3.
AntoniniABentiRDeNotarisR: La SPECT con Ioflupano (DaTSCAN) nel percorso diagnostico della malattia di Parkinson. Neurol Sci23: S321–S324, 2002.
4.
AntoniniAColomboGL: Il ruolo della SPECT in associazione a ioflupane nella diagnosi della Malattia di Parkinson: I risultati di un'esperienza. Farmeconomia e percorsi terapeutici3 (3): 125–133, 2002.
5.
CovelliEMVarroneABrunettiA: Imaging molecolare e funzionale nei parkinsonismi: Ruolo della medicina nucleare. Neurol Sci23: S325–S328, 2002.
6.
BenamerHTSPattersonJGrossetDG: Accurate Differentiation of Parkinsonism and Essential Tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Movement disorder15 (3): 503–510, 2000.
7.
TissinghGBooijJ: Iodine-123-N-Fluoropropyl-2 beta-Carbomethoxy-3beta-(4-Iodophenil) Tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med39: 1143–1148, 1998.
8.
SeibylJPMarekK: Iodine-123-beta-CIT and Iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med39: 1500–1508, 1998.
9.
BooijJTissinghG: [123I] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry62: 133–140, 1997.
10.
BooijJHemelaarJTGM: One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I] FPCIT SPECT. J Nucl Med40: 753–761, 1999.
11.
BooijJHabrakenJBA: Imaging of Dopamine Transporters with Iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med39: 1879–1884, 1998.
